Crinetics Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -261.57 M

Crinetics Pharmaceuticals, Inc. Operating Cash Flow is USD -261.57 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 46.58% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Crinetics Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -178.44 M, a 25.33% change year over year.
  • Crinetics Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -142.38 M, a 73.50% change year over year.
  • Crinetics Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -82.06 M, a 17.46% change year over year.
  • Crinetics Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -69.86 M, a 34.74% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities